Stay Informed With Our Latest Updates

Client Alert March 11, 2026

Royalty Finance in Life Sciences – Market Update 2026

This Royalty Finance Market Update provides an analysis of publicly reported royalty finance transactions for 2020 through 2025 in the …

Article December 17, 2025

Ryan Murr Writes in Buyouts About Potential for Strategic Use of Royalty Finance

Writing for Buyouts, partner Ryan Murr notes that in a rebounding biotech market, royalty finance can play a far more strategic role, provided it’s executed with disciplined underwriting, smart structuring, and a genuine partnership with innovators.

Royalty Finance Tracker

The Gibson Dunn team has represented clients in royalty finance transactions with a total aggregate value of approximately $8 Billion.

In the Media August 14, 2025

Gibson Dunn Life Sciences Partners Interviewed by Scrip

Partners Ryan Murr and Todd Trattner recently shared their insights about the rise of royalty financing deals in the market with Scrip (registration required), a Citeline Commercial publication

Webcasts May 12, 2025

Gibson Dunn and BCLT Host a Webcast Series on Royalty Finance, the UCC, and Issues of Recharacterization

In a three-part virtual series, BCLT & Gibson Dunn have partnered to discuss issues originally raised in a Law 360 article written by Gibson Dunn attorneys, Todd Trattner and Ryan Murr, entitled How Biotech Cos. Can Utilize Synthetic Royalty Financing.

Client Alert March 31, 2025

Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024

This Royalty Report provides an analysis of publicly reported royalty finance transactions for the last five years (2020 to 2024) in the life sciences sector, focusing on both traditional and synthetic royalty transactions.